A major shake-up in drug costs is coming — and it could change what millions of Americans pay at the pharmacy. Medicare has just unveiled significant price cuts for 15 widely used prescription medications, including some of the country’s most talked-about weight-loss drugs. But here’s what’s sparking debate: while the government will pay less, it’s not yet clear how much of those savings will actually reach patients.
Announced by the Centers for Medicare and Medicaid Services (CMS), these price reductions follow months of negotiations under the Inflation Reduction Act of 2022 — the same legislation that introduced historic cost caps for insulin. The newly lowered prices target drugs used to treat cancer, diabetes, asthma, and other long-term conditions that affect millions. The first round of negotiated prices for ten drugs is set to take effect in 2026; this latest batch of 15 will follow in 2027.
While these new 'negotiated prices' directly represent what Medicare pays pharmaceutical companies, patients’ out-of-pocket expenses may differ depending on individual insurance coverages. Still, CMS confirmed that the adjusted prices fall under the Maximum Fair Price policy — meaning all eligible Medicare participants must have access to these drugs through their Part D prescription plans.
Here’s a look at how the new negotiated prices will compare to current costs for a standard 30-day supply:
- Ozempic, Rybelsus and Wegovy (for Type 2 diabetes, cardiovascular health, and weight loss): $274, previously $959.
- Trelegy Ellipta (asthma, COPD): $175, down from $654.
- Xtandi (prostate cancer): $7,004, reduced from $13,480.
- Pomalyst (Kaposi sarcoma, multiple myeloma): $8,650, previously $21,744.
- Ofev (idiopathic pulmonary fibrosis): $6,350, down from $12,622.
- Ibrance (breast cancer): $7,871, previously $15,741.
- Linzess (irritable bowel syndrome, chronic constipation): $136, reduced from $539.
- Calquence (chronic lymphocytic leukemia and related cancers): $8,600, down from $14,228.
- Austedo and Austedo XR (Huntington’s disease-related chorea, tardive dyskinesia): $4,093, reduced from $6,623.
- Breo Ellipta (asthma, COPD): $67, down from $397.
- Xifaxan (hepatic encephalopathy, IBS with diarrhea): $1,000, previously $2,696.
- Vraylar (bipolar I disorder, depression, schizophrenia): $770, reduced from $1,376.
- Tradjenta (Type 2 diabetes): $78, down from $488.
- Janumet and Janumet XR (Type 2 diabetes): $80, down from $526.
- Otezla (psoriasis, psoriatic arthritis, Behçet’s disease): $1,650, down from $4,722.
Collectively, these 15 medications account for about $42.5 billion in Medicare Part D spending this year alone — nearly 15% of the program’s entire prescription drug budget. That figure underscores just how significant these price negotiations are for federal healthcare costs and, potentially, for patients’ wallets.
But this is where it gets controversial: some argue that drug companies might respond to these government-led negotiations by raising prices for private insurance patients or slowing down research and development for new treatments. Others believe it’s a long-overdue step toward curbing excessive medication costs in the U.S. health system.
So, what do you think — do these Medicare price cuts represent real progress in making healthcare more affordable, or are there hidden trade-offs that could backfire in the long run? Share your thoughts — especially if you or someone you know relies on one of these drugs.
